Document is current
Any future updates will be listed below
-
Authors
Jiang, Mengqi
Chen, Xi
Song, Yuanxiu
Wei, Mingyu
Cao, Jixiang
Lu, Wenjing
Lan, Feng
Bai, Yun
Cui, Ming https://orcid.org/0000-0002-1173-0645
-
Funding
Funding for this research was provided by:
Beijing Natural Science Foundation (7232088)
Beijing Research Ward Excellence Clinical Study Program (BRWEP2024W014090201)
Key Clinical Projects of Peking University Third Hospital (2024003)
National Natural Science Foundation of China (82070272)
- License Information
-
More Information
Article History
Received: 5 December 2024
Accepted: 23 June 2025
First Online: 26 July 2025
Declarations
:
: Human induced pluripotent stem cells (hiPSCs-U2 cell line) were obtained from Cellapy, with written consent from the donor. The consent form provided by Cellapy was shown in Supplementary Material Additional file 3. And the study was approved by the Ethics Committee of Beijing Anzhen Hospital (“Clinical genetic testing program for hereditary cardiovascular disease” on July 14, 2016, with Registration Number 2016015).
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
